205 related articles for article (PubMed ID: 18312403)
1. Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment.
Guerrero AL; Martín-Polo J; Laherrán E; Gutiérrez F; Iglesias F; Tejero MA; Rodríguez-Gallego M; Alcázar C
Eur J Neurol; 2008 Apr; 15(4):394-7. PubMed ID: 18312403
[TBL] [Abstract][Full Text] [Related]
2. Reduced serum uric acid levels in neuromyelitis optica: serum uric acid levels are reduced during relapses in NMO.
Min JH; Waters P; Vincent A; Lee S; Y Shin H; H Lee K; Kim BJ
Acta Neurol Scand; 2012 Oct; 126(4):287-91. PubMed ID: 22309305
[TBL] [Abstract][Full Text] [Related]
3. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
4. Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis.
Constantinescu CS; Freitag P; Kappos L
Mult Scler; 2000 Dec; 6(6):378-81. PubMed ID: 11212132
[TBL] [Abstract][Full Text] [Related]
5. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
[TBL] [Abstract][Full Text] [Related]
6. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
7. Serum uric acid levels and leukocyte nitric oxide production in multiple sclerosis patients outside relapses.
Mostert JP; Ramsaransing GS; Heersema DJ; Heerings M; Wilczak N; De Keyser J
J Neurol Sci; 2005 Apr; 231(1-2):41-4. PubMed ID: 15792819
[TBL] [Abstract][Full Text] [Related]
8. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
[TBL] [Abstract][Full Text] [Related]
9. [Experience in the treatment of multiple sclerosis with interferon beta in Galicia].
Romero-López J; Seijo-Martínez M; Del Campo V; Amigo-Jorrín MC; Arias M; Cortés-Laíño JA; Dapena-Bolaño D; López-González FJ; Lorenzo-González JR; Marín-Sánchez M; Muñoz-García D; Ozaita-Arteche G; Prieto JM
Rev Neurol; 2003 Dec 1-15; 37(11):1001-4. PubMed ID: 14669137
[TBL] [Abstract][Full Text] [Related]
10. Serum uric acid levels in patients with multiple sclerosis: a meta-analysis.
Liu B; Shen Y; Xiao K; Tang Y; Cen L; Wei J
Neurol Res; 2012 Mar; 34(2):163-71. PubMed ID: 22333889
[TBL] [Abstract][Full Text] [Related]
11. Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone).
Haas J; Firzlaff M
Eur J Neurol; 2005 Jun; 12(6):425-31. PubMed ID: 15885045
[TBL] [Abstract][Full Text] [Related]
12. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study.
Ghezzi A; Amato MP; Capobianco M; Gallo P; Marrosu G; Martinelli V; Milani N; Milanese C; Moiola L; Patti F; Pilato V; Pozzilli C; Trojano M; Zaffaroni M; Comi G;
Mult Scler; 2005 Aug; 11(4):420-4. PubMed ID: 16042224
[TBL] [Abstract][Full Text] [Related]
13. Serum uric acid levels in multiple sclerosis patients inversely correlate with disability.
Guerrero AL; Gutiérrez F; Iglesias F; Martín-Polo J; Merino S; Martín-Serradilla JI; Laherrán E; Tejero MA
Neurol Sci; 2011 Apr; 32(2):347-50. PubMed ID: 21327401
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
[TBL] [Abstract][Full Text] [Related]
15. Increased Serum Brain-derived Neurotrophic Factor in Multiple Sclerosis Patients on Interferon-β and Its Impact on Functional Abilities.
Mehrpour M; Akhoundi FH; Delgosha M; Keyvani H; Motamed MR; Sheibani B; Meysamie A
Neurologist; 2015 Oct; 20(4):57-60. PubMed ID: 26468869
[TBL] [Abstract][Full Text] [Related]
16. Uric acid: a potential biomarker of multiple sclerosis and of its disability.
Moccia M; Lanzillo R; Palladino R; Russo C; Carotenuto A; Massarelli M; Vacca G; Vacchiano V; Nardone A; Triassi M; Morra VB
Clin Chem Lab Med; 2015 Apr; 53(5):753-9. PubMed ID: 25241733
[TBL] [Abstract][Full Text] [Related]
17. Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis.
Guerrero AL; Tejero MA; Gutiérrez F; Martín-Polo J; Iglesias F; Laherran E; Martín-Serradilla JI; Merino S
Neurologia; 2011 Apr; 26(3):137-42. PubMed ID: 21163235
[TBL] [Abstract][Full Text] [Related]
18. Serum uric acid and multiple sclerosis.
Sotgiu S; Pugliatti M; Sanna A; Sotgiu A; Fois ML; Arru G; Rosati G
Neurol Sci; 2002 Oct; 23(4):183-8. PubMed ID: 12536287
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory treatment of multiple sclerosis in Norway.
Torkildsen Ø; Grytten N; Myhr KM
Acta Neurol Scand Suppl; 2007; 187():46-50. PubMed ID: 17419828
[TBL] [Abstract][Full Text] [Related]
20. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
